Publication

A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14.

Journal Paper/Review - Jan 7, 2022

Units
PubMed
Doi
Contact

Citation
Rentsch C, Roth B, Bosshard P, Püschel H, Boll D, Hefermehl L, Roghmann F, Gierth M, Ribi K, Schäfer S, Wicki A, Bubendorf L, Torpai R, Thalmann G, Lucca I, Kwiatkowski M, Wirth G, Strebel R, Engeler D, Pedrazzini A, Hüttenbrink C, Schultze-Seemann W, Hayoz S. A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14. Eur Urol Oncol 2022; 5:195-202.
Type
Journal Paper/Review (English)
Journal
Eur Urol Oncol 2022; 5
Publication Date
Jan 7, 2022
Issn Electronic
2588-9311
Pages
195-202
Brief description/objective

VPM1002BC is a genetically modified Mycobacterium bovis bacillus Calmette-Guérin (BCG) strain with potentially improved immunogenicity and attenuation.